The Definitive Industry Forum for
CKD Drug Development

Advance More Personalized Therapies for Rare & Common Kidney Diseases

The surge of clinical breakthroughs in SGLT2s, GLP-1s and ERAs for CKD, significant advancements to strengthen proteinuria and GFR slope as surrogates for long-term outcomes, and a wave of promising new targets in development, has truly lit the fuse on decades of innovative kidney research.

Bringing together 200+ biopharma stakeholders, from scientific research to clinical development and outcomes, across three days of concentrated discussion, the 6th CKD Drug Development Summit is the definitive forum for KOLs, industry experts, and regulators to concentrate kidney innovation onto the next generation of drug development.

From uncovering the genetic architecture of specific CKD subgroups and revolutionizing translatable models of renal pathophysiology, to breaking new ground in CKD trial design and implementing new therapies into the treatment paradigm, join Novo Nordisk, Boehringer Ingelheim, Eli Lilly, AstraZeneca, the FDA, Regeneron, Novartis and more to collaborate and drive progress of precision medicine and reinvent the landscape of rare and common kidney disease treatments.

Hear from 60+ World-Class Speakers

Join Like-Minded Attendees

Join Like-Minded Attendees

Hear What Our Past Attendees Say

“One of the few events in the calendar which brings together such a large group of world leading experts in kidney drug development from multiple fields, fully focused and dedicated on how to improve the care for patients living with kidney disease.”

Dominik Steubl, Senior Clinical Program Leader, Boehringer Ingelheim

“The power of this Summit comes from both the diversity of topics and the diversity of subject matter experts across Industry, Academia, Health Care Authorities, and Patient Groups.”

Manish Maski, Head, Global Rare Nephrology Medical Affairs, Sanofi

“A one-of-a-kind unique blend of leaders in the Nephrology community, industry and science discussing exciting advances in biology and treatment of kidney diseases.”

Dermot Reilly, Director, Genetics & Translational Biology, Johnson & Johnson

Our Partners

george clinical
antaros medical
ENYO Pharma
chinook_logo (002)

Download Event Guide

CKD Brochure Page 1 EB2

Other Events in the Series